Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Endocrinol Invest ; 40(9): 899-909, 2017 Sep.
Article in English | MEDLINE | ID: mdl-28283913

ABSTRACT

The clinical and public health relevance of gestational diabetes mellitus (GDM) is widely debated due to its increasing incidence, the resulting negative economic impact, and the potential for severe GDM-related pregnancy complications. Also, effective prevention strategies in this area are still lacking, and controversies exist regarding diagnosis and management of this form of diabetes. Different diagnostic criteria are currently adopted worldwide, while recommendations for diet, physical activity, healthy weight, and use of oral hypoglycemic drugs are not always uniform. In the present review, we provide an update of current insights on clinical aspects of GDM, by discussing the more controversial issues.


Subject(s)
Diabetes, Gestational/diagnosis , Diabetes, Gestational/therapy , Risk Reduction Behavior , Blood Glucose/metabolism , Diabetes, Gestational/blood , Diet/adverse effects , Diet/methods , Exercise/physiology , Female , Glucose Tolerance Test/methods , Humans , Hypoglycemic Agents/pharmacology , Hypoglycemic Agents/therapeutic use , Pregnancy
2.
Curr Drug Targets ; 12(2): 149-72, 2011 Feb.
Article in English | MEDLINE | ID: mdl-20887246

ABSTRACT

Triamcinolone acetonide (TA) is one of the first pharmacologic compounds evaluated for the treatment of choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). The most important effects of TA consist in the stabilisation of the blood-retinal barrier and the down-regulation of inflammation. TA also has anti-angiogenic and anti-fibrotic properties. The peculiar characteristic of being well tolerated by ocular tissues and the capability to remain active for many months after a single intravitreal injection, make this drug a safe and effective alternative. In the past decade, intravitreal injection of TA (IVTA) has emerged as a useful treatment of several ocular diseases such as uveitis, macular edema secondary to retinal vasculature disease, neovascularisation and vitreoretinopathy. In this paper, we review all the available evidence of its use in AMD as mono-therapy or in combination with other treatments, and we discuss which role TA will play in the treatment of AMD in the future. The first experiences with IVTA as monotherapy for the treatment of exudative AMD reported a positive outcome in transiently reducing the leakage from CNV. However, in the long-term follow-up, IVTA as monotherapy had no effect on the risk of severe visual acuity loss, despite a significant anti-angiogenic effect found 3 months after the treatment. Consequently, studies using the combination of IVTA and photodynamic therapy (PDT), which acts synergistically, were performed. They reported to improve vision and to reduce the number of re-treatments with PDT. A large number of publications confirmed the positive synergic role of combining TA and PDT (therapies) for the treatment of all types of CNV: classic or predominantly classic, occult or minimally classic and RAP (Retinal Angiomatous Proliferation) lesions. The advantages registered with the use of IVTA plus PDT compared to PDT alone were partially limited by the side effects, such as the rapid evolution of cataract. Nevertheless, cataract surgery may stimulate the development of CNV (result in stimulating CNV). However, in large, randomized, clinical trials on combination therapy of TA and PDT, visual acuity failed to show an improvement, even though the lesion size and subretinal fluid had decreased, compared to controls treated with PDT alone. Some authors reported an increased risk of developing macular atrophy after the combination therapy with IVTA and PDT. Reduction of the PDT fluence rate in association with the use of steroids resulted in reducing the risk of macular atrophy and in a better visual acuity outcome. The introduction of anti-VEGF-based drugs has revolutionized the treatment of AMD and has replaced all the previous therapies used for CNV. Visual improvement becomes an expectation in a higher proportion of patients, previously limited to minimizing vision loss. Anti-VEGF therapy also resulted in superior visual improvement compared to all types of combination therapy with IVT and PDT. Nevertheless, anti-VEGF monotherapy also has many limitations due to the need of repetitive treatments, increased costs and tachyphylaxis. Treatment regimens involving TA in combination therapy with anti-VEGF and PDT may preserve benefits for substantially longer periods. A question remains open on whether a combination treatment with anti-VEGF, triamcinolone and/or PDT may be a treatment option in patients with exudative AMD, by offering, with one cycle of therapy, functional VA benefits comparable to those observed with continued monthly anti-VEGF therapy. Further trials, of higher scientific significance, are needed to study the potential of these treatment options.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Macular Degeneration/drug therapy , Triamcinolone Acetonide/therapeutic use , Angiogenesis Inhibitors/adverse effects , Angiogenesis Inhibitors/therapeutic use , Animals , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents/adverse effects , Anti-Inflammatory Agents/pharmacology , Blindness/etiology , Blindness/prevention & control , Choroidal Neovascularization/drug therapy , Choroidal Neovascularization/etiology , Choroidal Neovascularization/prevention & control , Combined Modality Therapy/adverse effects , Combined Modality Therapy/trends , Delayed-Action Preparations/adverse effects , Delayed-Action Preparations/pharmacology , Delayed-Action Preparations/therapeutic use , Humans , Hyperthermia, Induced/adverse effects , Intravitreal Injections , Macular Degeneration/metabolism , Macular Degeneration/physiopathology , Macular Degeneration/therapy , Photochemotherapy/adverse effects , Photochemotherapy/trends , Photosensitizing Agents/adverse effects , Photosensitizing Agents/pharmacology , Photosensitizing Agents/therapeutic use , Porphyrins/adverse effects , Porphyrins/pharmacology , Porphyrins/therapeutic use , Triamcinolone Acetonide/administration & dosage , Triamcinolone Acetonide/adverse effects , Triamcinolone Acetonide/pharmacology , Vascular Endothelial Growth Factors/antagonists & inhibitors , Vascular Endothelial Growth Factors/metabolism , Verteporfin , Wet Macular Degeneration/drug therapy , Wet Macular Degeneration/metabolism , Wet Macular Degeneration/physiopathology , Wet Macular Degeneration/therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...